Related Experiment Videos
Issues in pediatric asthma
1Department of Child Health, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK. http://www.abdn.ac.uk/child health/chindex.htm
Insights
Diagnosing asthma in young children is challenging due to similar symptoms. Delaying inhaled corticosteroid (ICS) therapy until a clear diagnosis is established may be best, considering alternatives for mild cases.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Clinical Therapeutics
Background:
- Wheezing syndromes in young children are often misdiagnosed as asthma.
- Accurate differential diagnosis is crucial for effective treatment and improved outcomes.
- Inhaled corticosteroids (ICS) are standard for persistent pediatric asthma but raise concerns about overuse.
Purpose of the Study:
- To address the diagnostic challenges in differentiating pediatric asthma from other wheezing disorders.
- To evaluate the appropriateness of early and long-term inhaled corticosteroid (ICS) use in young children.
- To explore alternative treatments for mild asthma in pediatric populations.
Main Methods:
- Review of clinical presentations, pathophysiology, and disease evolution of pediatric wheezing disorders.
- Analysis of current treatment guidelines and evidence for inhaled corticosteroids (ICS) in pediatric asthma.
- Consideration of alternative therapeutic options, such as leukotriene receptor antagonists.
Main Results:
- Differentiating asthma from other wheezing disorders in young children is complex due to overlapping symptoms.
- Evidence supports ICS benefits in persistent pediatric asthma, but concerns exist regarding overuse in milder cases.
- Delayed ICS initiation until definitive diagnosis may prevent unnecessary steroid exposure.
Conclusions:
- Accurate differential diagnosis is essential for managing pediatric wheezing disorders.
- Clinicians should consider delaying regular ICS therapy in young children until a definitive asthma diagnosis is confirmed.
- Alternative treatments should be explored to mitigate potential side effects of ICS in mild pediatric asthma.
Abstract:
Different wheezing syndromes can carry the diagnostic label of "asthma," especially in very young children, and an accurate differential diagnosis is essential for improving outcomes. Because presenting symptoms are similar, making a rapid, accurate differential diagnosis is often daunting. Asthma can, eventually, be distinguished from other wheezing disorders based on differences in symptomatology, pathophysiology, and disease evolution. Once diagnosed, inhaled corticosteroids (ICS) remain the cornerstone of treatment in persistent pediatric asthma. Compelling evidence supports the benefits of these agents in reducing asthma-related morbidity and mortality and in preventing airway remodeling. As a result, ICS use in young children with asthma has grown substantially in recent years. Questions are being raised about the appropriateness of early and long-term use of ICS in young children, and whether ICS are overused in this population. Because of the challenges faced by clinicians in differentiating asthma from the other childhood wheezing disorders often present in young children, it may be best to delay the use of regular ICS therapy until a definitive diagnosis can be established. Alternatives to ICS (such as the leukotriene receptor antagonists) should also be considered to avoid the growth-suppressing potential of steroids in the management of mild asthma.